Clinical Trials Directory

Trials / Completed

CompletedNCT03413124

Bioavailability Study of MGL-3196 Tablets Compared to Capsules

A Single Center, Open-Label, Single-Dose, Cross-over, Bioavailability Study of MGL-3196 Tablets Compared to Capsules in Healthy Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
16 (actual)
Sponsor
Madrigal Pharmaceuticals, Inc. · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to compare the pharmacokinetics of MGL-3196 capsules with MGL-3196 tablets in healthy male subjects and female subjects not of child-bearing potential.

Conditions

Interventions

TypeNameDescription
DRUGMGL-3196 TabletMGL-3196 in Tablet form
DRUGMGL-3196 CapsuleMGL-3196 in Capsule form

Timeline

Start date
2018-02-05
Primary completion
2018-02-17
Completion
2018-03-13
First posted
2018-01-29
Last updated
2019-09-18

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT03413124. Inclusion in this directory is not an endorsement.

Bioavailability Study of MGL-3196 Tablets Compared to Capsules (NCT03413124) · Clinical Trials Directory